Literature DB >> 33881561

Endogenous cortisol excess confers a unique lipid signature and metabolic network.

Arturo Vega-Beyhart1,2, Marta Iruarrizaga3, Adriana Pané2, Guillermo García-Eguren1, Oriol Giró1, Laura Boswell1,2, Gloria Aranda1, Vanesa Flores1,2, Gregori Casals4, Cristina Alonso3, Mireia Mora1,2, Irene Halperin1,2, Francesc Carmona5, Joaquim Enseñat5, Oscar Vidal5, Ting Hu6, Gemma Rojo7,8, Ramon Gomis2,8,9,10, Felicia A Hanzu11,12,13,14.   

Abstract

Chronic cortisol excess induces several alterations on protein, lipid and carbohydrate metabolism resembling those found in the metabolic syndrome. However, patients exposed to prolonged high levels of cortisol in Cushing syndrome (CS) present exceeding cardiometabolic alterations not reflected by conventional biomarkers. Using 3 ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS) platforms, we aimed to characterise the serum metabolome of 25 patients with active endogenous CS and 25 control subjects matched by propensity score (sex, BMI, diabetes mellitus type 2 (T2D), high blood pressure (HBP) and dyslipidaemia) to search for potential disease-specific biomarkers and pathways associated to the clinical comorbidities. A total of 93 metabolites were significantly altered in patients with CS. Increased levels of sulfur amino acids (AA), triacylglycerols, glycerophospholipids, ceramides and cholesteryl esters were observed. Contrarily, concentrations of essential and non-essential AA, polyunsaturated fatty acids, conjugated bile acids and second messenger glycerolipids were decreased. Twenty-four-hour urinary free cortisol (24h-UFC) independently determined the concentration of 21 lipids and 4 AA. A metabolic signature composed by 10 AA and 10 lipid metabolites presented an AUC-ROC of 95% for the classification of CS patients. Through differential network analysis, 152 aberrant associations between metabolites involved in the Lands cycle and Kennedy pathway were identified. Our data indicates that chronic hypercortisolemia confers a unique lipidomic signature and several alterations in numerous AA even when compared to patients with similar metabolic comorbidities providing novel insights of the increased cardiometabolic burden of CS. KEY MESSAGES: • Cortisol excess induces metabolic alterations beyond conventional biomarkers. • The hypercortisolism extent determines the concentration of 21 lipids and 5 aa. • Cortisol excess confers a unique metabolic signature of 20 metabolites. • Kennedy and Lands cycle are profoundly disturbed by cortisol excess.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Biomarkers; Cortisol; Cushing syndrome; Lipidomics; Metabolomics

Mesh:

Substances:

Year:  2021        PMID: 33881561     DOI: 10.1007/s00109-021-02076-0

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  40 in total

1.  Mortality in Cushing's syndrome: systematic analysis of a large series with prolonged follow-up.

Authors:  G Ntali; A Asimakopoulou; T Siamatras; J Komninos; D Vassiliadi; M Tzanela; S Tsagarakis; A B Grossman; J A H Wass; N Karavitaki
Journal:  Eur J Endocrinol       Date:  2013-10-08       Impact factor: 6.664

2.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; John Newell-Price; Martin O Savage; Paul M Stewart; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2008-03-11       Impact factor: 5.958

Review 3.  Defining the metabolome: size, flux, and regulation.

Authors:  Nicola Zamboni; Alan Saghatelian; Gary J Patti
Journal:  Mol Cell       Date:  2015-05-21       Impact factor: 17.970

Review 4.  Cushing's syndrome.

Authors:  André Lacroix; Richard A Feelders; Constantine A Stratakis; Lynnette K Nieman
Journal:  Lancet       Date:  2015-05-21       Impact factor: 79.321

Review 5.  Endocrinology Meets Metabolomics: Achievements, Pitfalls, and Challenges.

Authors:  Janina Tokarz; Mark Haid; Alexander Cecil; Cornelia Prehn; Anna Artati; Gabriele Möller; Jerzy Adamski
Journal:  Trends Endocrinol Metab       Date:  2017-08-02       Impact factor: 12.015

6.  Sulfur amino acids in Cushing's disease: insight in homocysteine and taurine levels in patients with active and cured disease.

Authors:  Antongiulio Faggiano; Daniela Melis; Raffaele Alfieri; MariaCristina De Martino; Mariagiovanna Filippella; Francesco Milone; Gaetano Lombardi; Annamaria Colao; Rosario Pivonello
Journal:  J Clin Endocrinol Metab       Date:  2005-09-20       Impact factor: 5.958

Review 7.  Complications of Cushing's syndrome: state of the art.

Authors:  Rosario Pivonello; Andrea M Isidori; Maria Cristina De Martino; John Newell-Price; Beverly M K Biller; Annamaria Colao
Journal:  Lancet Diabetes Endocrinol       Date:  2016-05-10       Impact factor: 32.069

Review 8.  Metabolic syndrome in Cushing's syndrome.

Authors:  Philippe Chanson; Sylvie Salenave
Journal:  Neuroendocrinology       Date:  2010-09-10       Impact factor: 4.914

9.  Cortisol-related metabolic alterations assessed by mass spectrometry assay in patients with Cushing's syndrome.

Authors:  Guido Di Dalmazi; Marcus Quinkler; Timo Deutschbein; Cornelia Prehn; Nada Rayes; Matthias Kroiss; Christina M Berr; Günter Stalla; Martin Fassnacht; Jerzy Adamski; Martin Reincke; Felix Beuschlein
Journal:  Eur J Endocrinol       Date:  2017-05-31       Impact factor: 6.664

10.  Glucocorticoids promote hepatic cholestasis in mice by inhibiting the transcriptional activity of the farnesoid X receptor.

Authors:  Yan Lu; Zhijian Zhang; Xuelian Xiong; Xiaolin Wang; Jin Li; Guojun Shi; Jian Yang; Xianfeng Zhang; Huijie Zhang; Jie Hong; Xuefeng Xia; Guang Ning; Xiaoying Li
Journal:  Gastroenterology       Date:  2012-08-23       Impact factor: 22.682

View more
  2 in total

1.  Cushing's Disease Management: Glimpse Into 2051.

Authors:  Rinkoo Dalan; Stefan R Bornstein; Bernhard O Boehm
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-06       Impact factor: 6.055

2.  Metabolomic Abnormalities in Serum from Untreated and Treated Dogs with Hyper- and Hypoadrenocorticism.

Authors:  Carolin Anna Imbery; Frank Dieterle; Claudia Ottka; Corinna Weber; Götz Schlotterbeck; Elisabeth Müller; Hannes Lohi; Urs Giger
Journal:  Metabolites       Date:  2022-04-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.